^
    Back
    Association details:
    Biomarker:CD20 overexpression
    Cancer:Peripheral T-cell Lymphoma
    Drug:Rituxan (rituximab) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Medicine (Baltimore)
    Title:

    T-cell lymphoma with abundant CD20 expression showing a good response to rituximab with gemcitabine, oxiplatin, and L-asparaginase (R-pGEMOX): A case report

    Excerpt:
    A 65-year-old man was diagnosed with T-cell lymphoma with abundant CD20 expression…Upon admission to our department, he was administered a rituximab + gemcitabine + oxiplatin + L-asparaginase (R-pGEMOX) regimen and achieved partial remission.
    Secondary therapy:
    P-GEMOX
    DOI:
    10.1097/MD.0000000000010199.